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patients had a complete response and four had a partial
response, giving an overall response rate of 75%. Three
patients are alive from 6 to 21 months after HSCT. One
patient is well and two have chronic GVHD. Two patients
showed no response at all.
Thus, FMCs may be successfully used for immune
modulation and tissue repair.Table 1
ST2 concentrations at D14 predict GVHD development by D100 and predict
D180 NRM
UM FIC (n ¼ 414) UM RIC
(n ¼ 184)
DFCI
(n ¼ 75)
Hazard
Ratio
(HR)
P-
value
HR P-
value
HR P-
value
Age (55 and
Over vs.
Under 55)
1.5 0.01 0.8 0.4 0.1 0.02
Disease Status
(High vs.
Low risk)
1.0 0.99 1.8 0.02 n/a
Donor 1.9 <0.001 0.9 0.7 n/a59
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Fungal infection is a serious complication after allogeneic
hematopoietic stem cell transplantation but its impacts on
graft-versus host disease (aGVHD) remains to be elucidated.
a-mannan, one of the main components of fungal cell wall,
induces Th17 responses, leading to the elimination of fungi.
We therefore hypothesized that fungal infection could
modulate GVHD by inducing Th17 responses. Lethally irra-
diated B6D2F1 (H-2b/d) mice were injected with 4 x 106 BM
and 4 x 106 T cells from MHC-mismatched B6 (H-2b) donors
on day 0. Mice were intraperitoneally injected with 20mg of
a-mannan or diluent on day 1. GVHD was severe in mannan-
treated allogeneic mice, with 16.7% survival by day30,
whereas 83.3% of allogeneic controls survived this period
(Table). Histopathologic examination showed signiﬁcantly
exacerbation of GVHD pathology, especially in the lung, of
mannan-treated animals than in controls (Table).
A ﬂowcytometric analysis of the spleen and thymus after
BMT showed that administration of mannan did not alter
donor cell engraftment.
We then evaluated the roles of Th17 in aGVHD of
mannan-treated allogeneic models using IL-17-deﬁcient
mice as donors. Infusion of IL-17-/- T cells signiﬁcantly
improved GVHD clinical scores (3.5 0.4 vs 5.50.3 at day14,
P<.05), survival (62.5% vs 12.5% at day 30, P < .05) and
pulmonary GVHD pathology scores (1.00.5 vs 7.01.0 at
day21, P < .05) compared with those of mannan-treated
controls.
These results suggest that mannan can exacerbate acute
GVHD, mainly on pulmonary lesions.Th17 contribute to the
development of acute pulmonary GVHD in this model, and
that targeting Th17 may therefore represent a promising
therapeutic strategy for treating acute pulmonary GVHD.Table
Group Clinical
GVHD
scores
on
day+14
Survivals
on
day+30
(%)
Pathology Scores
Lung Liver Intestine
TCD Diluent 1.10.8 100 0 0.30.4 0.70.4
TCD a-mannan 1.20.5 100 0 0.70.8 0.50.5
+T Diluent 3.60.7 83.3 1.50.7 2.5 1.2 2.0 0.8
+T a-mannan 5.70.5y 16.7* 7.01.0y 4.0 1.8 2.5 0.8
TCD: T cell-depleted BMT, +T: T cell-repleted BMT.
Data are expressed as mean  SD.
* P < 0.01 vs control.
y P<0.05 vs control.60
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Acute GVHD is the primary limitation of allogeneic HSCT.
We have previously reported that plasma concentrations of
suppressor of tumorigenicity 2 (ST2) at the onset of GVHD
therapy predicted response at day (D) 28 and non-relapse
mortality (NRM) at D180 after therapy initiation. We
hypothesized that ST2measured early in HSCTwould predict
GVHD occurrence by D100 and D180 NRM after HSCT.
We measured ST2 in plasma taken at D0, D14 and D21
after HSCT in a pilot set. ST2 concentrations at D14weremost
different between patients who developed GVHD and those
without GVHD, and were twice higher in patients receiving
full intensity conditioning (FIC) compared to those receiving
reduced intensity conditioning (RIC). We then measured ST2
concentrations at D14 in two independent sets: 1) 598
patients from the University of Michigan (UM), 69% receiving
FIC (15% receiving TBI) and 31% receiving RIC HSCT, 2) 75
patients receiving unrelated, FIC (92% receiving TBI) HSCT
from the Dana Farber Cancer Institute (DFCI). UM patients
who developed GVHD were older and more likely to receive
mismatched or unrelated donor HSCT. Median day of GVHD
onset was D35 in FIC and D42 in RIC (p¼0.08). DFCI patients
who received sirolimus as GVHD prophylaxis were over-(Unrelated
vs. Related)
HLA match
(Mismatched
vs. Matched)
2.1 <0.001 1.0 0.9 2.7 0.09
ST2 Concentration
(High vs.
Low)*,y
1.5 0.004 1.3 0.3 2.0 0.08
Age 3.1 <0.001 0.7 0.4 0.7 0.5
Disease Status 1.1 0.6 2.7 0.02 n/a
Donor 1.5 0.1 1.1 0.8 n/a
HLA match 1.7 0.06 0.5 0.3 1.9 0.2
ST2 Concentration 2.8 <0.001 4.8 0.005 2.6 0.04
* Effect of ST2 calculated with regression models adjusting for age,
disease status, donor, and HLA match.
y High deﬁned as ST2 concentration >600 pg/mL for UM FIC, >300 pg/mL
for UM RIC, >1660 pg/mL for DFCI.
Abstracts / Biol Blood Marrow Transplant 19 (2013) S129eS149 S143represented in the no-GVHD group. As ST2 concentrations
differed between conditioning intensities, we used 3 models
for prediction using the median ST2 concentrations for UM
FIC, UM RIC, and DFCI FIC as cutpoints.
In multivariate analysis including the age, disease status,
donor source, and HLA match, high ST2 predicted the
development of GVHD in UM FIC, and trended toward
signiﬁcance in the DFCI set (Table 1 Top). Patients with high
ST2 at D14 were at increased risk of D180 NRM for all
conditioning intensities, independent of the clinical charac-
teristics (Table 1 Bottom). High ST2 was not associated with
increased risk of relapse mortality 1 year after HSCT.
In conclusion, high ST2 early in HSCT identiﬁes patients at
high risk for acute GVHD and NRM following HSCT. This has
therapeutic consequences including increased monitoring
and potential preemptive interventions.
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Bronchiolitis obliterans syndrome (BOS) after allogeneic
HSCT is associated with high mortality and unknown path-
ogenesis. We present interim results from a prospective
phase II trial evaluating of montelukast for the treatment of
BOS after HSCT and studying BOS biology. Montelukast
interrupts cysteinyl leukotriene activity and may diminish
homing of activated cells to bronchioles and ﬁbrosis. Twenty-
three patients have enrolled with stable or decreasing
immunosuppression for 3 months prior and BOS diagnosed
by modiﬁed NIH criteria; 2 were withdrawn, and 19 have
completed primary endpoint. Participants ranged from 15-72
years, 13/23 female, most had moderate to severe disease
with baseline FEV1 of 46% predicted (24-73), and median
FEV1/VC 0.5 (0.29-0.78). Montelukast was well-tolerated and
no patient required escalation of BOS-directed therapy
during the evaluation period. All patients met criteria for
treatment success (<15% decline in 6 months), with FEV1
either increased 5-13% of predicted (n¼5), stable (n¼7), or
declined 5-13% (n¼6). FEV1 slope of decline was generated
using regression line of FEV1 value vs. days post-HSCT. At 6
months, slope was improved in 9 patients, stable in 9,
declined in 1. Other manifestations of cGVHD showed: 5/8 GI
GVHD improved and 3/8 stable; 5/10 liver cGVHD improved,4/10 stable, 1 worse, using NIH consensus staging. Survival of
the study cohort is 90% (19/21); 2 year survival is 84% (10/12),
twice published data (44%). Bronchoalveolar lavage (BAL)
from in non-infected patients at baseline revealed cysteinyl
leukotriene receptor expression on CD4 and CD8 T cells,
granulocytes, and eosinophils, thereby potentially impli-
cating these populations in BOS biology. While blood
leukotriene receptor expression on CD4 cells was similar to
normal donors, CD4 proportion was signiﬁcantly reduced in
BOS patients (P < 0.01). Other blood receptor levels of these
populations were similar between normal donors and
controls, although CD8 T cells trended toward decreased
receptor expression after treatment at 6 months and
decreased proportion of CD8 T cells at 2 years (p<0.04). B
cells were absent in BAL while present in blood. These data
suggest that: 1) montelukast is a safe and effective therapy
for BOS after allogeneic HSCT; 2) T cells, granulocytes, and
eosinophils (though not B cells) were associated with BOS in
BAL; and 3) cysteinyl leukotrienes may be a point of regu-
lation in the progression of BOS after HSCT.62
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Acute graft-versus-host disease (aGVHD) is primarily a T-
cell mediated process. Uric acid released from dying cells acts
as a danger signal that alerts the immune system to cell
death and promotes cytotoxic T cell responses. Elimination of
uric acid in mouse models reduces this immune response.
We hypothesized that lower serum uric acid levels at the
time of transplant may decrease the incidence of aGVHD.
Through record review, we recorded serum uric acid levels
from day -7 through day +6 from 43 historical control
patients who received myeloablative HCT (MRD, n¼32;
MUD, n¼11) at the Massachusetts General Hospital between
2007 and 2010, these patients received standard allopurinol.
We also obtained uric acid levels from 23 consecutive
patients (19-59 years) with hematologic malignancies in
complete remission (AML, n¼13; ALL, n¼8; MDS, n¼1; MPD,
n¼1) who were treated in a pilot trial using rasburicase as
part of a myeloablative conditioning regimen, followed by
GCSF-mobilized HLA-matched (MRD, n¼18; MUD, n¼5)
peripheral blood HCT. Urate oxidase (Rasburicase) was
administered beginning on the ﬁrst day of conditioning at
a dose of 0.20 mg/kg IV daily for 5 days starting from day -7.
GVHD prophylaxis for all patients consisted of cyclosporine
or tacrolimus/MTX for MRD transplants and tacrolimus/
MTX/ +/-ATG for MUD transplants. Out of the control group,
patients who developed aGVHD (grade 2+) had a similar
mean serum uric acid level over all days (2.82 mg/dl)
compared to patients who did not have aGVHD (2.86 mg/dl,
